News | August 15, 2014

First Human Implants of VenTouch Ventricular Reshaping Device Performed in Malaysia

Global clinical trial in patients with functional mitral valve regurgitation underway

August 15, 2014 — Mardil Medical announced earlier this year the first-in-human implants using the VenTouch ventricular reshaping device performed by a surgical team at the Institut Jantung Negara (IJN) National Heart Institute in Kuala Lumpur, Malaysia. This novel, investigational device was implanted in two patients with severe functional mitral valve regurgitation (FMR), which was reduced to only trace amounts after implantation. The patients are part of a multicenter, global clinical study.

Jeswant Dillon, M.D., clinical director of adult surgery, and Mohd Azhari Yakub, M.D., chief cardiothoracic surgeon, performed the implantations at IJN. The first patient presented several challenges due to severe FMR combined with significant heart dilation and poor left ventricular function.

“After implantation of the VenTouch system’s therapy device, the patient’s mitral valve regurgitation was reduced to trace amounts and the patient was moved out of the intensive care unit the following day,” said Dillon. “Our heart team was fascinated with the ease of placement, the immediate performance of the therapy device and the rapid recovery of the very sick patients.”

The procedures were also attended and supported by William Cohn, M.D., FACS, FACCP, FAHA, director of minimally invasive cardiac surgery at the Texas Heart Institute in Houston; Eugene Grossi, M.D., director of cardiac research at New York University Medical Center; and Vivek Rao, M.D., Ph.D., MSc, FRCSC, chief of cardiac surgery at Toronto General Hospital.

“The VenTouch system is a promising technology that addresses both the annular and muscular abnormalities associated with FMR,” said Cohn. “I was extremely impressed with the marked reduction in regurgitation we were able to demonstrate after a quick, off-pump procedure through a small incision.”

FMR occurs when the left ventricle of the heart is enlarged and the mitral valve no longer closes properly. With each heartbeat, blood leaks backwards into lungs, creating debilitating symptoms. If left untreated, FMR overloads the heart and can lead to or accelerate heart failure. The current treatment for FMR is repairing the mitral valve, an open-heart surgical procedure on a bypass pump, which can be difficult to perform and risky for sicker patients. Even after successful repair surgery, FMR can reoccur because the ventricle often continues to get larger.

"Having now successfully treated patients with the VenTouch system, Mardil has taken an important step towards our goal of introducing this ground breaking therapy and giving FMR patients a promising and significantly less invasive treatment option,” said Jim Buck, president and CEO of Mardil Medical.

The VenTouch system is the only device that treats the root cause of FMR – the enlarged, injured left ventricle. The system’s delivery tool deploys the therapy device through a small incision between the ribs and guides it over the beating heart. The therapy device is a biomaterial sleeve fitted with an inflatable, adjustable fluid chamber which applies prescriptive pressure to a targeted location in order to realign valve leaflets, stopping the leaking by improving the shape and reducing the stress of the enlarged heart. If any further changes in the left ventricle occur after implantation, the VenTouch can be adjusted using a remote port.

For more information: www.mardil.com

Related Content

Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
The ChordArt transcatheter mitral valve leaflet chord replacement system on X-ray, showing the anchoring sections of the artificial chord.

The ChordArt transcatheter mitral valve leaflet chord replacement system on X-ray, showing the anchoring sections of the artificial chord.

News | Heart Valve Technology| August 01, 2017
Aug.
Hitachi and West Virginia University Partner to Advance Left Ventricular Mechanical Function Evaluation
News | Cardiovascular Ultrasound| July 21, 2017
Hitachi Healthcare and the West Virginia University Heart and Vascular Institute announced the formation of a new...
Edwards Sapien 3 TAVR valve will be implanted in asymptomatic aortic stenosis patients in the EARLY TAVR Trial
Feature | Heart Valve Technology| July 14, 2017
July 14, 2017 — Morristown Medical Center, part of Atlantic Health System, has randomized the first patient in the wo
Ziosoft's PhyZiodynamics 4-D processing showing a replaced aortic valve

An example of Ziosoft's PhyZiodynamics 4-D processing showing a replaced aortic valve.

Technology | Computed Tomography (CT)| July 12, 2017
July 12, 2017 — At the 2017 annual meeting for the Society of Cardiovascular Computed Tomography (SCCT), Ziosoft show
Medtronic's CoreValve Evolut R gained FDA approval for intermediate risk patients

An illustration of the self-expanding CoreValve Evolut R TAVR valve half deployed in the aortic root.

Feature | Heart Valve Technology| July 10, 2017
The U.S. Food and Drug Administration (FDA) has cleared an additional indication to expand the use Medtronic's self-...
HAART 300 Aortic Annuloplasty Device Sees U.S. Pilot Launch, First Commercial Use
News | Annuloplasty Rings| July 05, 2017
July 5, 2017 — BioStable Science & Engineering Inc.
Novel Approach May Improve Valve Function in Some Patients

Image courtesy of Messas, et al. JACC Basic to Translational Medicine.

News | Heart Valve Technology| June 30, 2017
June 30, 2017 — Pulsed cavitation ultrasound can be used to remotely soften human degenerative calcified biosprosthet
Overlay Init